Compare Merck & Co., Inc. (MRK) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Spotify Technology — how do they compare? Merck & Co., Inc. trades at $145.68 (market cap $351.28B), while Spotify Technology trades at $528.93 (market cap $108.22B). The key difference: Merck & Co., Inc. is far larger — about 3.2× Spotify Technology's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Spotify Technology for 111 Days on average.
| MRK | SPOT | |
|---|---|---|
Market Cap | $351.28B | $108.22B |
Volume | 7,969,665 | 1,655,796 |
Sector | Health | Media |
52-Week High | $156.43 | $692.04 |
52-Week Low | $82.49 | $412.75 |
Typical Hold Time | 98 Days | 111 Days |
Enterprise Value | $398.04B | $98.23B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Spotify (SPOT) trades at $524.71, up 2.3% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamental improvement with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income of $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst sentiment remains positive with 62% buy ratings and a $606.50 consensus price target.
The outlook remains favorable with continued revenue growth and margin expansion driving upside potential. Key risks include competitive pressures in streaming and market volatility. With strong institutional support and improving cash flow trends, SPOT presents a growth opportunity despite recent technical overbought conditions near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
